发明名称 |
HDAC INHIBITOR AND BTK INHIBITOR COMBINATIONS |
摘要 |
Disclosed herein are methods and compounds for treating an individual diagnosed with chronic lymphocytic leukemia (CLL) or acute myeloid leukemia (AML) by administering to the individual a combination comprising ibrutinib and Abexinostat. Also provided are methods for treating an ibrutinib-resistant CLL or an ibrutinib-resistant AML by administering to the individual a combination comprising ibrutinib and Abexinostat. Further provided are methods of reducing the development of ibrutinib resistance in an individual having either CLL or AML or preventing the development of ibrutinib resistance in an individual having CLL or AML by administering to the individual a combination comprising ibrutinib and Abexinostat. |
申请公布号 |
US2015352116(A1) |
申请公布日期 |
2015.12.10 |
申请号 |
US201514731173 |
申请日期 |
2015.06.04 |
申请人 |
Pharmacyclics LLC |
发明人 |
SAMPATH Deepa |
分类号 |
A61K31/519;C12Q1/68;A61K31/343 |
主分类号 |
A61K31/519 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method for treating chronic lymphocytic leukemia (CLL) in an individual in need thereof, comprising administering to the individual a combination comprising ibrutinib and Abexinostat. |
地址 |
Sunnyvale CA US |